Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Canale

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Journal of Lipid Mediators and Cell Signalling|March 1, 1994
Evidence for a role of platelet activating factor in hypovolemic shock in the ratB Zingarelli, F Squadrito, F Bussolino, et al.
Pharmacological Research|March 1, 1996
Endotoxin tolerance impairs a pertussis-toxin-sensitive G-protein regulating tumour necrosis factor release by macrophages from tumour-bearing ratsD Altavilla, F Squadrito, P Canale, et al.
Journal of Cardiovascular Pharmacology|January 1, 1994
Protective effects of L-659,989, a platelet-activating factor receptor antagonist, in myocardial ischemia and reperfusion in ratsM Ioculano, F Squadrito, D Altavilla, et al.
Pharmacology|December 1, 1994
Beneficial effects of BAY u3405, a novel thromboxane A2 receptor antagonist, in splanchnic artery occlusion shockP Canale, F Squadrito, D Altavilla, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 1996
Protection of ischemic and reperfused rat myocardium by the nonglucocorticoid 21-aminosteroid U-74389G, a new inhibitor of lipid peroxidationG M Campo, F Squadrito, D Altavilla, et al.
European Journal of Pharmacology|November 3, 1995
G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesisD Altavilla, F Squadrito, P Canale, et al.
British Journal of Pharmacology|December 1, 1994
Participation of tumour necrosis factor and nitric oxide in the mediation of vascular dysfunction in splanchnic artery occlusion shockF Squadrito, D Altavilla, P Canale, et al.
Cancer Research|August 18, 2018
CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8<sup>+</sup> T Cells-ResponseFernando P Canale, María C Ramello, Nicolás Núñez, et al.
Agents and Actions|July 1, 1993
Reduction of myocardial leukocyte accumulation and myocardial infarct size following administration of BAY u3405, a thromboxane A2 receptor antagonist, in myocardial ischaemia-reperfusion injuryF Squadrito, M Ioculano, D Altavilla, et al.
Pharmacology|September 1, 1993
G619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, reduces myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion in ratsF Squadrito, M Ioculano, D Altavilla, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Journal of Lipid Mediators and Cell Signalling|March 1, 1994
Evidence for a role of platelet activating factor in hypovolemic shock in the ratB Zingarelli, F Squadrito, F Bussolino, et al.
Pharmacological Research|March 1, 1996
Endotoxin tolerance impairs a pertussis-toxin-sensitive G-protein regulating tumour necrosis factor release by macrophages from tumour-bearing ratsD Altavilla, F Squadrito, P Canale, et al.
Journal of Cardiovascular Pharmacology|January 1, 1994
Protective effects of L-659,989, a platelet-activating factor receptor antagonist, in myocardial ischemia and reperfusion in ratsM Ioculano, F Squadrito, D Altavilla, et al.
Pharmacology|December 1, 1994
Beneficial effects of BAY u3405, a novel thromboxane A2 receptor antagonist, in splanchnic artery occlusion shockP Canale, F Squadrito, D Altavilla, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 1996
Protection of ischemic and reperfused rat myocardium by the nonglucocorticoid 21-aminosteroid U-74389G, a new inhibitor of lipid peroxidationG M Campo, F Squadrito, D Altavilla, et al.
European Journal of Pharmacology|November 3, 1995
G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesisD Altavilla, F Squadrito, P Canale, et al.
British Journal of Pharmacology|December 1, 1994
Participation of tumour necrosis factor and nitric oxide in the mediation of vascular dysfunction in splanchnic artery occlusion shockF Squadrito, D Altavilla, P Canale, et al.
Cancer Research|August 18, 2018
CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8<sup>+</sup> T Cells-ResponseFernando P Canale, María C Ramello, Nicolás Núñez, et al.
Agents and Actions|July 1, 1993
Reduction of myocardial leukocyte accumulation and myocardial infarct size following administration of BAY u3405, a thromboxane A2 receptor antagonist, in myocardial ischaemia-reperfusion injuryF Squadrito, M Ioculano, D Altavilla, et al.
Pharmacology|September 1, 1993
G619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, reduces myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion in ratsF Squadrito, M Ioculano, D Altavilla, et al.
Pageof 6